The global GLP-1 receptor agonist market is estimated to be valued at US$ 12,720.6 million in 2021 and is expected to exhibit a CAGR of 6.1% over the forecast period 2021-2028, as highlighted in a new report published by Coherent Market Insights.

A) Market Overview:

GLP-1 receptor agonists are a class of drugs used for the management of type 2 diabetes. They work by stimulating the GLP-1 receptors in the pancreas to increase insulin secretion and decrease glucagon release. This helps in controlling blood glucose levels and promoting weight loss. GLP-1 receptor agonists have gained significant attention in recent years due to their effectiveness in achieving glycemic control and their potential to reduce cardiovascular risk factors.

B) Market Dynamics:

The market for GLP-1 receptor agonists is driven by two main factors: the rising prevalence of diabetes and the increasing focus on disease management.

One of the key drivers propelling the growth of this market is the increasing prevalence of diabetes globally. According to the International Diabetes Federation, in 2019, approximately 463 million adults were living with diabetes worldwide, and this number is expected to reach 700 million by 2045. The growing diabetic population creates a substantial demand for effective diabetes management drugs, including GLP-1 receptor agonists.

Another driver for the market growth is the increasing focus on disease management. Governments and healthcare organizations across the globe are actively promoting the early diagnosis and effective management of chronic diseases like diabetes. This has led to a greater emphasis on the use of pharmacological interventions, such as GLP-1 receptor agonists, to achieve optimal glycemic control and reduce the risk of diabetes-related complications.

C) Segment Analysis:

The GLP-1 receptor agonist market can be segmented based on the type of GLP-1 receptor agonist and distribution channel. By type, the market is dominated by the exenatide segment, which held the largest market share in 2021. Exenatide-based GLP-1 receptor agonists, such as Byetta and Bydureon, have been widely prescribed due to their efficacy in achieving glycemic control and weight reduction in patients with type 2 diabetes.

D) PEST Analysis:

– Political:

Government initiatives to control diabetes through various awareness programs and policies influence the adoption of GLP-1 receptor agonists.

– Economic:

The economic burden of diabetes and its complications creates a significant market opportunity for GLP-1 receptor agonists.

– Social:

Increasing awareness about diabetes management and the importance of lifestyle modifications contribute to the market
growth of GLP-1 receptor agonists.

– Technological:

Advancements in drug delivery systems and the development of once-weekly formulations enhance patient convenience and compliance.

E) Key Takeaways:

– The global GLP-1 receptor agonist market is expected to witness high growth, exhibiting a CAGR of 6.1% over the forecast period, due to the increasing prevalence of diabetes and the focus on disease management.

– North America is the fastest-growing and dominating region in the global GLP-1 receptor agonist market, driven by the high prevalence of diabetes and the presence of key players in the region.

– The key players operating in the global GLP-1 receptor agonist market include Eli Lilly and Company, GlaxoSmithKline plc, Novo Nordisk A/S, PegBio Co., Ltd., AstraZeneca, Intarcia Therapeutics, Inc., Amylin Pharmaceuticals, Inc., Sanofi, Hanmi Pharm. Co., Ltd., Pfizer Inc., Amgen Inc., Innovent Biologics, Jiangsu Hengrui Medicine Co., Sun Pharmaceuticals Industries Ltd., and 9 Meters Biopharma, Inc. These players focus on product development, collaborations, and acquisitions to gain a competitive edge in the market.

In conclusion, the global GLP-1 receptor agonist market is experiencing significant growth due to the increasing prevalence of diabetes and the focus on disease management. The market is expected to witness further growth in the coming years, driven by advancements in drug delivery systems and the development of new formulations.